The Hamps Bio IPO, launched on December 13, 2024, attracted significant investor interest with a 6.48x overall subscription rate and 11.76x demand from retail investors. The IPO closed on December 17, with allotment status released on December 18.
- IPO Size: ₹6.22 crore.
- Issue Price: ₹51 per share.
- Listing Date: Expected on December 20, 2024, on the BSE SME.
- Lot Size: 2,000 shares, requiring a minimum investment of ₹1,02,000.
- GMP Today: ₹46, indicating a potential listing price of ₹97, almost 100% premium over the issue price.
Subscription Details
| Category | Times Subscribed |
|---|---|
| Retail Investors | 1,342.04x |
| Non-Institutional Investors (NIIs) | 758.27x |
| Qualified Institutional Buyers (QIBs) | No allocation |
Business Overview
Hamps Bio operates in two primary divisions:
- Pharma Division:
Marketing and distribution of pharmaceutical formulations like tablets, syrups, capsules, and injectables across 8 states in India. - FMCG Division:
Manufacturing freeze-dried and frozen products such as fruits, vegetables, herbs, and flowers, catering to 4 countries and 22 states in India.
The company uses both traditional distributor networks and e-commerce platforms like Amazon, Flipkart, and Jio Mart for sales.
GMP and Market Sentiment
- Grey Market Premium (GMP): ₹46.
- Estimated Listing Price: ₹97 per share (100% premium).
- Investor Sentiment: Strong interest indicates robust demand for Hamps Bio shares in the SME segment.
Financial Performance
- Revenue Streams:
- Pharma products dominate the domestic market.
- FMCG exports cater to international clients.
- Distributor Network: Over 50 distributors across key territories, strengthening market presence.
Analyst Recommendations
Why You Should Consider Investing:
- Strong GMP: The 100% premium in the grey market signals high demand and potential listing gains.
- Subscription Rates: Exceptional oversubscription by retail and NII categories highlights robust investor confidence.
- Growth Potential: Diversified operations across pharma and FMCG sectors cater to both domestic and international markets.
- E-commerce Penetration: Leveraging online platforms enhances reach and scalability.
Risks to Consider:
- SME IPO Risks: Investments in SME IPOs carry higher risks due to limited liquidity and smaller market sizes.
- Reliance on Pharma Sector: Heavy reliance on the pharmaceutical business could expose the company to regulatory and market risks.
How to Check Allotment Status
- Via BSE Website:
- Visit BSE Allotment Link.
- Enter IPO details and application number to check status.
- Via Bigshare Services:
- Visit Bigshare IPO Status Link.
- Provide relevant details to view allotment.
FAQs
1. What is the GMP for Hamps Bio IPO?
The GMP today is ₹46, indicating a strong potential listing price of ₹97 per share.
2. What is the minimum investment required?
The minimum investment is ₹1,02,000 for 2,000 shares.
3. When will Hamps Bio shares list?
The shares are expected to list on December 20, 2024, on the BSE SME.
4. What is the primary use of IPO proceeds?
Funds will be utilized for purchasing plant and machinery for the FMCG division, brand visibility, and general corporate expenses.
5. How was the subscription response?
The IPO was oversubscribed 1,057x overall, with 11.76x subscription from retail investors.
6. Is Hamps Bio IPO suitable for listing gains?
The strong GMP and subscription rates suggest a high likelihood of listing gains.
7. What is the company’s primary business?
Hamps Bio specializes in pharma formulations and FMCG freeze-dried products, catering to both domestic and international markets.
8. What are the risks of investing in SME IPOs?
SME IPOs carry higher risks, including limited liquidity, smaller scale operations, and market volatility.
Click here to know more.
